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Abstract: With the improvement in survival rate, cardiotoxicity has emerged as a significant adverse
effect of cancer therapy. Early diagnosis of subclinical cardiac injury may allow the initiation
of cardioprotective therapy and preventing the interruption of optimal cancer therapy and the
development of irreversible cardiac dysfunction. In this article, we review the role of two-dimensional
speckle tracking echocardiography (2D-STE), beyond the common left ventricle global longitudinal
strain in the diagnosis of early subclinical cardiac injury in patients treated with cancer therapies.
Keywords: cardiotoxicity; cardio-oncology; speckle tracking; global longitudinal strain; left atrial
strain; right ventricle strain; diastolic strain
1. Introduction
Over the last several decades, the advance in cancer therapies has led to a significant
increase in survival rate, with over 16 million cancer survivors in the United States to
date [1]. The improvement in survival has exposed the scope of long-term side effects, with
cardiovascular disease (CVD) being a leading cause of morbidity and mortality [2]. Al-
though anthracyclines (ANT) are still considered as the most familiar cardiotoxic drugs [3],
monoclonal antibodies against human epidermal growth factor receptor 2 (HER2), vascular
endothelial growth factor inhibitors (VEGFi), tyrosine kinase inhibitors (TKI), proteasome
inhibitors (PI), immune checkpoint inhibitors (ICIs) and mediastinal radiation have been all
recognized to have cardiotoxic effect [4,5]. The most common definition of cardiotoxicity is
cancer therapeutics-related cardiac dysfunction (CTRCD) which is based on left ventricular
Ejection Fraction (LVEF) evaluation [3,6]. Cardiotoxicity it is not limited solely to left
ventricle (LV) dysfunction, but can be expressed as acute coronary syndrome, arrhythmias,
valvular disease, pericardial disease, systemic and pulmonary hypertension [5,7].
Numerous studies have shown that detection of early cardiac injury is crucial and
may lead to full or partial recovery of the LV function with early intervention, either by
adjusting the cancer therapy or by initiating cardioprotective treatment [3,8,9]. Currently,
two-dimensional (2D) echocardiography is the method of choice for the evaluation of car-
diotoxicity during cancer therapy, using mainly LVEF assessment [6]. LVEF has a number
of limitations, including inter- and intra-observer variability, load-dependency and changes
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evident only after significant myocardial damage occurs. Therefore, there is a need for a
more sensitive tool for the detection of small subclinical changes in cardiac function [6,10].
Both three-dimensional (3D) echocardiography and cardiac magnetic resonance (CMR)
have improved inter- and intra-observer variability, with higher sensitivity and lower
false-negative rate and are therefore more reliable and accurate tools in the assessment of
LVEF and cardiac function in cancer patients [11,12]. Despite their advantages both exams
are not routinely used for the assessment of patients treated with cancer therapies due to
the lack of accessibility, trained staff and relatively high cost.
In recent years, there is a rising use of 2D speckle tracking echocardiography (2D-
STE), for the measurement of myocardial deformation as a marker of contractility and
elasticity [6]. The use of 2D-STE is feasible, partially by using automated image analysis.
However, since 2D-STE strongly depends on image quality, visual check should be per-
formed constantly. Furthermore, 2D-STE is considered angle-independent, comparing to
LVEF and in contrast to tissue Doppler imaging [13] and has the ability to differentiate
active versus passive movement [14]. Two-dimensional-STE has a number of limitations
including load dependency as it is decreases in the presence of decreased preload, increased
afterload and increased heart rate [13]. Importantly, cut-off values for myocardial dys-
function are vendor-specific [15]. It is strongly recommended to use the same ultrasound
machine and the same 2D speckle-tracking software for longitudinal analysis evaluation
and follow up [16]. Recently, vendor-independent software packages (TOMTEC Imaging
Systems GMBH, Germany) showed improved correlation between the measured values
using different vendors. Currently, global longitudinal strain (GLS) is considered to be a
sensitive marker of cardiac injury in cancer patients [6,12,17], yet other 2D-STE utilities
should be explored.
In this paper we focus on present and future role of 2D-STE, beyond the commonly
used LV GLS, for the early diagnosis of subclinical cardiac injury in patients treated with
cancer therapies.
2. LV Global Longitudinal Strain
Longitudinal strain is derived from apical images reflecting the changes in the distance
between two segments of the heart relative to their baseline distance apart [18] (Figure 1).
LV GLS was reported to be a marker of subclinical LV dysfunction with high correlation to
CMR measurements [19] and stronger association with prognosis, compared to LVEF, in
non-cancer population [14,20]. Other observational studies showed the potential use of
LV GLS reduction as a predictor for LVEF reduction in cancer patients [21,22] and in the
prevention of the cessation of cancer therapies [23]. The benefit of LV GLS reduction as
an early marker for cardiac injury was seen both in patients treated with ANT [24,25], as
well as in other cancer populations [17,26], including patients diagnosed with ICIs-related
myocarditis [27]. Recently, Pourier et al. [28] showed that strain values decreased during
ANT treatment and an ongoing reduction were seen at the latest follow-up (>5 years after
therapy with ANT) with preserved cardiac function. Accordingly, it is considered as the
optimal parameter for the early detection of subclinical LV dysfunction by the Society of
Echocardiography and the European Association of Cardiovascular Imaging [6].
Overall, the accepted normal cutoff value for LV GLS is ≤−18% [12]. A study by
Negishi et al. [29] showed that the stronger predictor of CTRCD development was a
LV GLS relative reduction of 11% and above during cancer therapy. Whereas relative
reduction below 8% is considered not meaningful, a relative reduction above 15% is
clinically significant. The latter is supported by the recent position statements [12]. While
abnormal baseline or relative changes in LV GLS has been well studied and described
as predictors for LV dysfunction and worse prognosis [12], there is little evidence to
support initiation of cardioprotective therapy guided by GLS changes [3,30]. The recently
published multicenter randomized SUCCOUR trial was designed to compare whether LV
GLS versus LVEF-guided approach for cardioprotective therapy initiation will prevent
LVEF reduction and CTRCD development [31]. Overall, 307 patients exposed to ANT
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therapy and had additional heart failure risk, were included. Significant LV GLS relative
reduction was determined as ≥12% for the initiation of cardioprotective treatment. At a
1-year follow-up, while no significant change in LVEF was observed between the two arms,
fewer patients were diagnosed with CTRCD in the LV GLS-guided group and LVEF was
higher. This important trial support for the first time the use of LV GLS for the initiation of
cardioprotective therapy and the need for more randomized trials [31].




Figure 1. Left ventricle global longitudinal strain measurement GLS was assessed in three apical views, 4 chamber, 2 
chamber and 3 chamber views, with 6 segments measured per each view (presented in the different colors), with a total 
of 18 segments per each exam. 
Overall, the accepted normal cutoff value for LV GLS is ≤−18% [12]. A study by 
Negishi et al. [29] showed that the stronger predictor of CTRCD development was a LV 
GLS relative reduction of 11% and above during cancer therapy. Whereas relative reduc-
tion below 8% is considered not meaningful, a relative reduction above 15% is clinically 
significant. The latter is supported by the recent position statements [12]. While abnormal 
baseline or relative changes in LV GLS has been well studied and described as predictors 
for LV dysfunction and worse prognosis [12], there is little evidence to support initiation 
of cardioprotective therapy guided by GLS changes [3,30]. The recently published multi-
center randomized SUCCOUR trial was designed to compare whether LV GLS versus 
LVEF-guided approach for cardioprotective therapy initiation will prevent LVEF reduc-
tion and CTRCD development [31]. Overall, 307 patients exposed to ANT therapy and 
had additional heart failure risk, were included. Significant LV GLS relative reduction was 
determined as ≥12% for the initiation of cardioprotective treatment. At a 1-year follow-up, 
while no significant change in LVEF was observed between the two arms, fewer patients 
were diagnosed with CTRCD in the LV GLS-guided group and LVEF was higher. This 
important trial support for the first time the use of LV GLS for the initiation of cardiopro-
tective therapy and the need for more randomized trials [31]. 
3. LV Circumferential and Radial Strain 
Both LV global circumferential strain (LV GCS) (−20.9% to −27.8%, mean −23.3%) and 
LV radial strain (LV GRS) (35.1% to 59.0%, mean 47.3%) have wide range of normal values 
[32]. The lower reproducibility of these measurements, mainly LV GRS, makes the identi-
fication of changes during or post cancer therapy challenging. Emerging data have shown 
that LV GCS is decreased during ANT therapy [33] and can predict cardiotoxicity devel-
opment [34]. In cancer survivors, LV GCS and LV GRS were consistently abnormal, in the 
Figure 1. Left ventricle global longitudinal strain measurement GLS was assessed in three apical views, 4 chamber,
2 chamber and 3 chamber views, with 6 segments measured per each view (presented in the different colors), with a total of
18 segments per each exam.
3. LV Circumferential and Radial Strain
Both LV global circumferential strain (LV GCS) (−20.9% to −27.8%, mean −23.3%)
and LV radial strain (LV GRS) (35.1% to 59.0%, mean 47.3%) have wide range of normal
values [32]. The lower reproducibility of these measurements, mainly LV GRS, makes the
identification of changes during r post cancer therapy chall ging. Eme gi g data have
shown that LV GCS is decrease uring ANT therapy [33] and can pred ct cardio oxicity
dev lopme t [34]. In cancer survivors, LV GCS and LV GRS ere consistently abnormal,
in the presence of normal LVEF. Although a reduction in peak systolic L GRS of 6% to
17% [34] may indicate early myocardial changes, these changes have been less consistent
with the development of LV dysfunction or heart failure comparing to LV GLS [14,34]. A
systemic review evaluating 1504 patients during or after cancer chemotherapy concluded
that the clinical value of LV GCS and LV GRS in predicting cardiotoxicity is limited and
that LV GLS appears to be the preferred measurement [20].
4. Multi-Layers Strain
Commonly, the myocardial wall is subdivided into an epicardial, mid-myocardial, and
endocardial layers. However, the clinical value of layer-specific assessment is questionable,
mainly ue o low visibility of the wall for tracking [13]. Although contr ctile force is
greater in the endocar ial layer than in the epicardial layer [35], it is also more susceptible
to injury due to its higher energy requi ements. Previous studies have demonstrated that
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layer specific strain is more accurate for discriminating the various intensities of trans-
mural scarring compared to CMR [36]. Layer-specific strain analysis provides additional
information on disease progression compared to LV GLS alone in cases of heart failure,
hypertensive cardiomyopathy, aortic stenosis, and ischemia [35,37]. In a recent study by
Chang et al. [38] LV endocardial strain was significantly reduced after three cycles of ANT
therapy compared to epicardial strain, despite no significant changes in routine LV systolic
and diastolic parameters. The decline in endocardial values prior to LVEF changes suggests
that myocardial injury begins from the endocardial layer. However, according to the 2014
European Association of Cardiovascular Imaging (EACVI) expert consensus statement
reduction was seen in all three strain layers of the myocardium with no specific prefer-
ence [6,24]. To date the value of layer-specific strain in cancer patients is considered limited
and contradicting [20] and therefore there is no recommendation for its use for surveillance.
5. Diastolic Strain
Diastolic dysfunction is considered common among cancer patients; yet no clear
evidence has shown that it can predict future LV systolic dysfunction [6]. Diastolic strain
has the advantages of being less angle dependent and evaluating directly the relaxation
of the ventricles rather than indirect measurements of filling pressures. Using 2D-STE
for the evaluation of diastolic function, specifically global diastolic strain rate, has been
shown to have prognostic value regarding cardiovascular morbidity and mortality in the
general population [39,40]. However, information is lacking in cancer patients [41]. A
study by Stoodley et al. showed changes in diastolic strain rate among breast cancer
patients treated with chemotherapy with association for LV dysfunction development [41].
Recently, Hochstadt et al. evaluated the role of diastolic strain time and slope, measuring
manually the lengthening of the myocardium during diastole (Figure 2). Among cancer
patients, diastolic strain time and slope showed high correlation to the routine diastolic
echocardiography parameters. Furthermore, change in Diastolic strain time and slope was
associated with systolic dysfunction development [42,43]. Due to limited data and small
trials, diastolic strain is not currently performed as part of the routine evaluation of 2D-STE
in cancer population.




Figure 2. Diastolic strain time (Dst) measurement. Dst was evaluated by measuring manually the 
time of lengthening (ms) of the myocardium during diastole, from the point of aortic valve closure 
(AVC) throughout the isovolumic relaxation time and early diastolic, until the plateau of the 
curve. Dst was assessed in three apical views, 4 chamber, 2 chamber and 3 chamber views, with 6 
segments measured per each view (presented in the different colors), with a total of 18 segments 
per each exam. The red arrow shows how the measurement was performed manually for the aver-
age of the 6 segments in the 4-chamber view. 
6. Left Atrial Strain 
The left atrium (LA) plays an important role in the regulation of filling pressure and 
LV diastolic function. The LA functions as a reservoir to blood returning from the pulmo-
nary veins, as a conduit to blood flowing during early diastole to the LV and as a pump 
contracting in late diastole (Figure 3). Left atrial strain (LAS) provide a more accurate 
evaluation of the diastolic function, compared to the routine echocardiographic parame-
ters [44], as determined by invasive measurement (wedge pressure) [45]. LAS evaluation 
is considered more feasible as it can be calculated from a single apical four-chamber view 
and is independent to mitral valve pathology. Decreased LAS, with LAS reservoir (LASr) 
specifically, was found useful in predicting cardiovascular outcomes in healthy and heart 
failure populations [46,47]. LASr value below 35% is considered as diastolic dysfunction 
[48]. A recent study conducted on pediatric patients after ANT therapy found a significant 
decrease in LAS [49]. In contrast, Santoro et al. did not find significant changes in LAS 
among adult patients during ANT exposure [50]. Furthermore, to date there is no data 
regarding the predictive value of relative change in LAS on cardiac outcomes. 
Figure 2. Diastolic strain time (Dst) measurement. Dst was evaluated by measuring manually the time of lengthening (ms)
of the myocardium during diastole, from the point of aortic valve closure (AVC) throughout the isovolumic relaxation time
and early diastoli , until the plateau of the curve. Dst was assessed in three apic l views, 4 chamber (A), 2 chamber (B) and
3 chamber (C) views, with 6 segments measured per each view (presented in the different col rs), with a total of 18 segments
per each exam. The red arrow shows how the measurement was performed manually for the average of the 6 segments in the
4-chamber view.
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6. Left Atrial Strain
The left atrium (LA) plays an important role in the regulation of filling pressure
and LV diastolic function. The LA functions as a reservoir to blood returning from the
pulmonary veins, as a conduit to blood flowing during early diastole to the LV and as
a pump contracting in late diastole (Figure 3). Left atrial strain (LAS) provide a more
accurate evaluation of the diastolic function, compared to the routine echocardiographic
parameters [44], as determined by invasive measurement (wedge pressure) [45]. LAS eval-
uation is considered more feasible as it can be calculated from a single apical four-chamber
view and is independent to mitral valve pathology. Decreased LAS, with LAS reservoir
(LASr) specifically, was found useful in predicting cardiovascular outcomes in healthy
and heart failure populations [46,47]. LASr value below 35% is considered as diastolic
dysfunction [48]. A recent study conducted on pediatric patients after ANT therapy found
a significant decrease in LAS [49]. In contrast, Santoro et al. did not find significant changes
in LAS among adult patients during ANT exposure [50]. Furthermore, to date there is no
data regarding the predictive value of relative change in LAS on cardiac outcomes.




Figure 3. Left atrial strain measurement. Region of interest of the left atrial endocardial border, from the mitral annulus 
level to the pulmonary veins and/or LA appendage orifice, up to the opposite mitral annulus side were assessed. LASr = 
left atrial strain during reservoir phase (yellow arrow); LASc = left atrial strain during conduit phase (blue dot arrow); 
LASp = left atrial strain during atrial contraction phase (green arrow). 
7. Right Ventricle Strain 
There is a rising interest in the use of RV global longitudinal strain (RV GLS) in dif-
ferent populations, with an observation of reduced RV GLS in both preserved and re-
duced heart failure patients [51] (Figure 4). Data on RV dysfunction in cancer patients 
remain limited and currently the prognostic value of RV dysfunction is unknown [6]. This 
may be the result of the inaccurate methods of RV evaluation, including fractional area 
changes and tricuspid annular plane systolic excursion (TAPSE). A number of studies 
showed that RV GLS and RV free wall longitudinal strain (RV FWLS) decrease during 
cancer treatment [52,53]. RV GLS impairment seems to develop almost simultaneously 
with LV GLS impairment in breast cancer patients. However, the long-term prognostic 
implications of RV deformation mechanics are unknown. In breast cancer patients receiv-
ing ANT, the decline of RV FWLS correlated significantly with the development of dysp-
nea, independently of LV systolic and diastolic function [54]. Furthermore, in patients 
with stage III non-small-cell lung cancer under concurrent chemotherapy and radiother-
apy, the baseline and change of RV FWLS have been proven to be an independent predic-
tor of all-cause mortality, with worse prognosis in patients presenting with a RV FWLS ≥ 
10.1% decrease [55]. 
Figure 3. Left atri l strain measurem nt. Region of inter st of the left atrial endocardial border, from the mitral an u-
lus l l t t e pul onary veins and/or LA appendage orifice, up to the opposite mitral annulus sid were a sessed.
LASr = left atrial strain during reservoir phase (yellow arrow); LASc = left atrial strain during conduit phase (blue dot
arrow); LASp = left atrial strain during atrial contraction phase (green arrow).
7. Right Ventricle Strain
There is a rising interest in the use of RV global longitudinal strain (RV GLS) in
different populations, with an observation of reduced RV GLS in both preserved and
reduced heart failure patients [51] (Figure 4). Data on RV dysfunction in cancer patients
remain limited and currently the prognostic value of RV dysfunction is unknown [6]. This
may be the result of the inaccurate methods of RV evaluation, including fractional area
changes and tricuspid annular plane systolic excursion (TAPSE). A number of studies
showed that RV GLS and RV free wall longitudinal strain (RV FWLS) decrease during
cancer treatment [52,53]. RV GLS impairment seems to develop almost simultaneously
with LV GLS impairment in breast cancer patients. However, the long-term prognostic
implications of RV deformation mechanics are unknown. In breast cancer patients receiving
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ANT, the decline of RV FWLS correlated significantly with the development of dyspnea,
independently of LV systolic and diastolic function [54]. Furthermore, in patients with
stage III non-small-cell lung cancer under concurrent chemotherapy and radiotherapy, the
baseline and change of RV FWLS have been proven to be an independent predictor of
all-cause mortality, with worse prognosis in patients presenting with a RV FWLS ≥ 10.1%
decrease [55].




Figure 4. Right ventricle strain measurement. Region of interest of the right ventricle (RV) was defined by the endocardial 
border at the lateral tricuspid annulus level to the medial tricuspid annulus level. Then, the software automatically divided 
the apical right chamber views in 6 segments (three separate basal, mid and septal RV free wall strain traces, and three 
separate basal, mid and septal RV septal wall strain traces) and mathematically calculated RV global 4-chamber contour 
(RV4CSL) by averaging values of equal segment strain. Peak strain was defined as the peak value during entire heart cycle 
that may coincide with end-systolic peak or may appear after aortic valve closure. End systole (ES) was defined by the 
tricuspid valve opening time or by nadir of volume curve as surrogate. Segmental longitudinal strain curves. Note, free-
wall strain segments are usually higher than septal strain segments. 
The normal cut-off value of RV GLS is considered—18.2% and above [51]. The pro-
posed cutoff value of relative percent decrease RV GLS to identify cardiotoxicity is con-
sidered 14.8% and above, similar to that of LV GLS [3]. 
Clearly, the role of RV is emerging as a marker of cardiac injury in cancer patients 
and may be at least as frequent as LV injury. However, its prognostic value remains to be 
proven by large prospective studies. 
8. Right Atrial Strain 
Wright et al. [56] evaluated the correlation between right atrial strain (RAS) measure-
ment and invasive measurement of right atrial pressure (RAP), showing an association 
with right atrial (RA) size, right ventricle (RV) systolic function and inferior vena cava 
(IVC) size. Among HF patients, RA conduit and reservoir function are independent pre-
dictors of mortality [57]. To the best of our knowledge there is no data regarding the role 
of RAS as predictor for early acute cardiotoxicity development in cancer patients. 
9. Conclusions 
CV imaging prior to the beginning of cancer therapy provides estimation of preexist-
ing cardiac damage and establishes baseline information for future changes. Currently 
there are recommendation for baseline and serial LVEF follow-up only among patients 
treated with ANT and trastuzumab (a type of HER2 targeted therapy) [58], however, these 
Figure 4. Right ventricle strain measurement. Region of interest of the right ventricle (RV) was defined by the endocardial
border at the lateral tricuspid annulus level to the medial tricuspid annulus level. Then, the software automatically divided
the apical right chamber views in 6 segments (three separate basal, mid and septal RV free wall strain traces, and three
separate basal, mid and septal RV septal wall strain traces) and mathematically calculated RV global 4-chamber contour
(RV4CSL) by averaging values of equal segment strain. Peak strain was defined as the peak value during e tire heart
cy le that may c incide with end-systolic peak or may appear after ortic valve closure. End systole (ES) was defined by
the tricuspid valve opening time or by nadir of volume curve as surrogate. Segmental longitudinal strain curves. Note,
free-wall strain segments are usually higher than septal strain segments.
The norm l cut-off value of RV GLS is considered—18.2% and bove [51]. The pro
posed cutoff v lue of relative pe cen decrease RV GLS to identify cardiotoxicity is consid-
ered 14.8% and ab ve, similar to that of LV GLS [3].
Clearly, th role of RV is emerging as a marker of cardiac injury in cancer patients
and may be at least as frequent as LV injury. However, its prognostic value remains to be
proven by large prospective studies.
8. Right Atrial Strain
Wright et al. [56] evaluated the correlation between right atrial strain (RAS) measure-
ment and invasive measurement of right atrial pressure (RAP), showing an association
with right atrial (RA) size, right ventricle (RV) systolic function and inferior vena cava (IVC)
size. Among HF patients, RA conduit and reservoir function are independent predictors of
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mortality [57]. To the best of our knowledge there is no data regarding the role of RAS as
predictor for early acute cardiotoxicity development in cancer patients.
9. Conclusions
CV imaging prior to the beginning of cancer therapy provides estimation of preex-
isting cardiac damage and establishes baseline information for future changes. Currently
there are recommendation for baseline and serial LVEF follow-up only among patients
treated with ANT and trastuzumab (a type of HER2 targeted therapy) [58], however, these
recommendations are not consistently applied. Recently a position paper by the Heart Fail-
ure Association (HFA), EACVI and European Society of Cardiology (ESC) recommended
a more frequent and personalized echocardiography surveillance according to the spe-
cific cancer therapy [12]. However, LVEF screening remains sub-optimal and decision
concerning the interruption of potentially lifesaving therapy should not rely solely on
LVEF changes.
2D-STE is a reliable and sensitive marker of early cardiac injury with a high availability,
low cost, no radiation and no nephrotoxic effect compared to other cardiac imaging modal-
ities. It is recommended to use the same vendor’s machine and software version during
serial follow-up examinations [6]. Early reduction in myocardial deformation appears to
forecast the development of subsequent cardiotoxicity, with 2D-STE and especially LV GLS
being the most consistent parameter [20], even before LV function deteriorates.
While the high value of LV GLS is well recognized, 2D-STE has wide and less familiar
modalities, specifically diastolic strain, LAS and RV GLS that are showing a promising role
in the diagnosis of early sub-clinical cardiac injury in patients treated with cancer therapies.
Future large randomized studies are needed in order to evaluate the role of all 2D-STE
modalities in cancer patients, both as a routine surveillance as well as a dictating tool for
the beginning of cardioprotective therapy.
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